Xoma Corp.’s (XOMA) “Outperform” Rating Reaffirmed at Wedbush
Xoma Corp. (NASDAQ:XOMA)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a research note issued on Wednesday. They currently have a $17.00 target price on the stock. Wedbush’s price target would suggest a potential upside of 172.44% from the stock’s previous close.
Other equities research analysts also recently issued reports about the company. Zacks Investment Research upgraded Xoma Corp. from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research report on Wednesday, August 10th. Jefferies Group reiterated a “hold” rating on shares of Xoma Corp. in a research report on Friday, August 5th. Finally, Cowen and Company reissued a “market perform” rating on shares of Xoma Corp. in a research note on Monday, September 19th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Xoma Corp. currently has a consensus rating of “Hold” and a consensus target price of $4.61.
Xoma Corp. (NASDAQ:XOMA) traded down 17.1026% during midday trading on Wednesday, reaching $5.1728. The company’s stock had a trading volume of 248,657 shares. Xoma Corp. has a 12-month low of $0.34 and a 12-month high of $7.33. The company’s 50-day moving average is $0.68 and its 200 day moving average is $0.67. The firm has a market cap of $623.75 million, a price-to-earnings ratio of 470.2545 and a beta of 2.87.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/xoma-corp-s-xoma-outperform-rating-reaffirmed-at-wedbush.html
Xoma Corp. (NASDAQ:XOMA) last posted its earnings results on Wednesday, August 3rd. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.01. The company earned $0.40 million during the quarter, compared to the consensus estimate of $0.84 million. During the same quarter in the prior year, the company earned ($0.20) EPS. Equities analysts forecast that Xoma Corp. will post ($0.47) earnings per share for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in XOMA. Bellevue Group AG acquired a new position in Xoma Corp. during the first quarter worth approximately $174,000. Geode Capital Management LLC boosted its position in Xoma Corp. by 1.3% in the first quarter. Geode Capital Management LLC now owns 600,488 shares of the company’s stock worth $464,000 after buying an additional 7,576 shares in the last quarter. Wedbush Securities Inc. boosted its position in Xoma Corp. by 4.1% in the second quarter. Wedbush Securities Inc. now owns 404,396 shares of the company’s stock worth $223,000 after buying an additional 15,827 shares in the last quarter. Paloma Partners Management Co acquired a new position in Xoma Corp. during the second quarter worth approximately $185,000. Finally, Spark Investment Management LLC boosted its position in Xoma Corp. by 100.9% in the second quarter. Spark Investment Management LLC now owns 203,900 shares of the company’s stock worth $112,000 after buying an additional 102,400 shares in the last quarter. 17.13% of the stock is currently owned by hedge funds and other institutional investors.
About Xoma Corp.
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
Receive News & Ratings for Xoma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xoma Corp. and related companies with MarketBeat.com's FREE daily email newsletter.